{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:28Z","timestamp":1790188228027,"version":"4.1.0"},"reference-count":131,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Conjugation of polyethylene glycol (PEGylation) to blood proteins and cells has\nemerged as a successful approach to address some of the issues attributed to the storage of blood\nproducts, including their short half-life and instability. In this regard, this review study aims to\ncompare the influence of different PEGylation strategies on the quality of several blood products\nlike red blood cells (RBCs), platelets, plasma proteins, i.e., albumin, coagulation factor VIII, and\nantibodies. The results indicated that conjugating succinimidyl carbonate methoxyPEG\n(SCmPEG) to platelets could improve blood transfusion safety by preventing these cells from\nbeing attached to low-load hidden bacteria in blood products. Moreover, coating of 20 kD succin- imidyl valerate (SVA)-mPEG to RBCs was able to extend the half-life and stability of these cells\nduring storage, as well as immune camouflage their surface antigens to prevent alloimmunisation.\nAs regards albumin products, PEGylation improved the albumin stability, especially during sterilization,\nand there was a relationship between the molecular weight (MW) of PEG molecules and\nthe biological half-life of the conjugate. Although coating antibodies with short-chain PEG molecules\ncould enhance their stabilities, these modified proteins were cleared from the blood faster.\nAlso, branched PEG molecules enhanced the retention and shielding of the fragmented and\nbispecific antibodies. Overall, the results of this literature review indicate that PEGylation can be\nconsidered a useful tool for enhancing the stability and storage of blood components.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666230522091958","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T05:32:30Z","timestamp":1684819950000},"page":"247-267","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pegylation, a Successful Strategy to Address the Storage and Instability\nProblems of Blood Products: Review 2011-2021"],"prefix":"10.2174","volume":"25","author":[{"given":"Tahereh Zadeh","family":"Mehrizi","sequence":"first","affiliation":[{"name":"Vaccine Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mirzaei","sequence":"additional","affiliation":[{"name":"Iran Ministry of Health and Medical\nEducation, Deputy Ministry for Education, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi Shafiee","family":"Ardestani","sequence":"additional","affiliation":[{"name":"Department of Radiopharmacy, Faculty of Pharmacy, Tehran\nUniversity of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"s9","volume":"8","author":"Hess J.R.","year":"2010","unstructured":"Hess J.R.; Conventional blood banking and blood component storage regulation: opportunities for improvement. Blood Transfus  2010,8(S3),s9-s15","journal-title":"Blood Transfus"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e000371","DOI":"10.1136\/tsaco-2019-000371","volume":"5","author":"Medvecz A.","year":"2020","unstructured":"Medvecz A.; Bernard A.; Hamilton C.; Schuster K.M.; Guillamondegui O.; Davenport D.; Transfusion rates in emergency general surgery: High but modifiable. Trauma Surg Acute Care Open  2020,5(1),e000371","journal-title":"Trauma Surg Acute Care Open"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s11427-011-4190-x","volume":"54","author":"Wang D.","year":"2011","unstructured":"Wang D.; Kyluik D.L.; Murad K.L.; Toyofuku W.M.; Scott M.D.; Polymer-mediated immunocamouflage of red blood cells: Effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells. Sci China Life Sci  2011,54(7),589-598","journal-title":"Sci China Life Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/CH-152037","volume":"64","author":"Tarasev M.","year":"2016","unstructured":"Tarasev M.; Chakraborty S.; Light L.; Davenport R.; Impact of environment on red blood cell ability to withstand mechanical stress. Clin Hemorheol Microcirc  2016,64(1),21-33","journal-title":"Clin Hemorheol Microcirc"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2130007","DOI":"10.1142\/S1793292021300073","volume":"16","author":"Mehrizi T.Z.","year":"2021","unstructured":"Mehrizi T.Z.; Hemocompatibility and hemolytic effects of functionalized nanoparticles on red blood cells: A recent review study. Nano  2021,16(8),2130007","journal-title":"Nano"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jpp\/rgab089","volume":"74","author":"Zadeh Mehrizi T.","year":"2022","unstructured":"Zadeh Mehrizi T.; Amini Kafiabad S.; Evaluation of the effects of nanoparticles on the therapeutic function of platelet: A review. J Pharm Pharmacol  2022,74(2),179-190","journal-title":"J Pharm Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2174\/1566524021666210928152015","volume":"22","author":"Mehrizi T.Z.","year":"2022","unstructured":"Mehrizi T.Z.; An overview of the latest applications of platelet-derived microparticles and nanoparticles in medical technology 2010-2020. Curr Mol Med  2022,22(6),524-539","journal-title":"Curr Mol Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1039\/D1NA00119A","volume":"3","author":"Zadeh M.T.","year":"2021","unstructured":"Zadeh M.T.; Mousavi H.K.; An overview on the investigation of nanomaterials\u2019 effect on plasma components: Immunoglobulins and coagulation factor VIII, 2010\u20132020 review. Nanoscale Adv  2021,3(13),3730-3745","journal-title":"Nanoscale Adv"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.29252\/jmp.19.74.39","volume":"19","author":"Zadeh M.T.","year":"2020","unstructured":"Zadeh M.T.; Pirali H.M.; Ebrahimi S.H.; Mirzaei M.; Shafiee A.M.; Haji M.H.M.; Mosaffa N.; Khamesipour A.; Javanmard A.; Rezazadeh S.; Ramezani A.; Effective materials of medicinal plants for leishmania treatment in vivo environment. Faslnamah-i Giyahan-i Daruyi  2020,19(74),39-62","journal-title":"Faslnamah-i Giyahan-i Daruyi"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.5812\/archcid.80314","volume":"13","author":"Zadeh M.T.","year":"2018","unstructured":"Zadeh M.T.; Mosaffa N.; Shafiee A.M.; Khamesipour A.; Ebrahimi S.H.; Pirali H.M.; In vivo therapeutic effects of four synthesized antileishmanial nanodrugs in the treatment of Leishmaniasis. Arch Clin Infect Dis  2018,13(5)","journal-title":"Arch Clin Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12291-013-0355-7","volume":"29","author":"Shahabi J.","year":"2014","unstructured":"Shahabi J.; Shahmabadi H.E.; Alavi S.E.; Movahedi F.; Esfahani M.K.M.; Mehrizi T.Z.; Akbarzadeh A.; Effect of gold nanoparticles on properties of nanoliposomal hydroxyurea: an in vitro study. Indian J Clin Biochem  2014,29(3),315-320","journal-title":"Indian J Clin Biochem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12291-013-0364-6","volume":"29","author":"Fatemeh D.R.A.","year":"2014","unstructured":"Fatemeh D.R.A.; Ebrahimi S.H.; Abedi A.; Alavi S.E.; Movahedi F.; Koohi M.E.M.; Zadeh M.T.; Akbarzadeh A.; Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: last status. Indian J Clin Biochem  2014,29(3),333-338","journal-title":"Indian J Clin Biochem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1566524021666210708154736","volume":"18","author":"Mehrizi T.Z.","year":"2022","unstructured":"Mehrizi T.Z.; Ardestani M.S.; Kafiabad S.A.; A review study of the influences of dendrimer nanoparticles on stored platelet in order to treat patients (2001-2020). Curr Nanosci  2022,18(3),304-318","journal-title":"Curr Nanosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5045\/br.2021.2021094","volume":"56","author":"Mehrizi T.Z.","year":"2021","unstructured":"Mehrizi T.Z.; Kafiabad S.A.; Eshghi P.; Effects and treatment applications of polymeric nanoparticles on improving platelets\u2019 storage time: A review of the literature from 2010 to 2020. Blood Res  2021,56(4),215-228","journal-title":"Blood Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2130013","DOI":"10.1142\/S1793292021300139","volume":"16","author":"Mehrizi T.Z.","year":"2021","unstructured":"Mehrizi T.Z.; Impact of metallic, quantum dots and carbon-based nanoparticles on quality and storage of albumin products for clinical use. Nano  2021,16(14),2130013","journal-title":"Nano"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2174\/1567201818666210316111941","volume":"18","author":"Mehrizi T.Z.","year":"2021","unstructured":"Mehrizi T.Z.; Rezayat S.M.; Ardestani M.S.; Shahmabadi H.E.; Ramezani A.; A review study about the effect of chitosan nanocarrier on improving the efficacy of amphotericin b in the treatment of leishmania from 2010 to 2020. Curr Drug Deliv  2021,18(9),1234-1243","journal-title":"Curr Drug Deliv"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"11759","DOI":"10.1038\/s41598-018-30103-7","volume":"8","author":"Zadeh M.T.","year":"2018","unstructured":"Zadeh M.T.; Shafiee A.M.; Haji M.H.M.; Khamesipour A.; Mosaffa N.; Ramezani A.; Novel nanosized chitosan-betulinic acid against resistant leishmania major and first clinical observation of such parasite in kidney. Sci Rep  2018,8(1),11759","journal-title":"Sci Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.2147\/IJN.S220410","volume":"14","author":"Zadeh M.T.","year":"2019","unstructured":"Zadeh M.T.; Khamesipour A.; Shafiee A.M.; Ebrahimi A.H.; Haji M.H.M.; Mosaffa N.; Ramezani A.; Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus. Int J Nanomedicine  2019,14,7593-7607","journal-title":"Int J Nanomedicine"},{"key":"ref=19","first-page":"143","volume":"11","author":"Zadeh M.T.","year":"2020","unstructured":"Zadeh M.T.; Mosaffa N.; Khamesipour A.; Haji M.H.M.; Ebrahimi S.H.; Shafiee A.M.; A novel nanoformulation for reducing the toxicity and increasing the efficacy of betulinic acid using anionic globular dendrimer. J Nanostruct  2020,11(1),143-152","journal-title":"J Nanostruct"},{"key":"ref=20","author":"Mangla S.","year":"2016","unstructured":"Mangla S.;  Engineering PEGylated Antibody Fragments for Enhanced Properties and Cancer Detection  2016","journal-title":"Engineering PEGylated Antibody Fragments for Enhanced Properties and Cancer Detection"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","volume":"252","author":"Abuchowski A.","year":"1977","unstructured":"Abuchowski A.; van Es T.; Palczuk N.C.; Davis F.F.; Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem  1977,252(11),3578-3581","journal-title":"J Biol Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.ijpx.2019.100019","volume":"1","author":"Freches D.","year":"2019","unstructured":"Freches D.; Rocks N.; Patil H.P.; Perin F.; Van Snick J.; Vanbever R.; Cataldo D.; Preclinical evaluation of topically-administered PEGylated Fab\u2019 lung toxicity. Int J Pharm X  2019,1,100019","journal-title":"Int J Pharm X"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"D\u2019souza A.A.","year":"2016","unstructured":"D\u2019souza A.A.; Shegokar R.; Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv  2016,13(9),1257-1275","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1021\/mp500658w","volume":"12","author":"Roque C.","year":"2015","unstructured":"Roque C.; Sheung A.; Rahman N.; Ausar S.F.; Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigen-binding fragment (Fab\u2019). Mol Pharm  2015,12(2),562-575","journal-title":"Mol Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40268-020-00297-1","volume":"20","author":"Bj\u00f8rnsdottir I.","year":"2020","unstructured":"Bj\u00f8rnsdottir I.; St\u00f8vring B.; S\u00f8eborg T.; Jacobsen H.; Sternebring O.; Plasma polyethylene glycol (PEG) levels reach steady state following repeated treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct\u00ae). Drugs R D  2020,20(2),75-82","journal-title":"Drugs R D"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/JBM.S82457","volume":"7","author":"Wynn T.","year":"2016","unstructured":"Wynn T.; Gumuscu B.; Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med  2016,7,121-128","journal-title":"J Blood Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1248\/bpb.b13-00661","volume":"37","author":"Zhang F.","year":"2014","unstructured":"Zhang F.; Liu M.; Wan H.; Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull  2014,37(3),335-339","journal-title":"Biol Pharm Bull"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"Garay R.P.","year":"2012","unstructured":"Garay R.P.; El-Gewely R.; Armstrong J.K.; Garratty G.; Richette P.; Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv  2012,9(11),1319-1323","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/hae.13875","volume":"26","author":"Baumann A.","year":"2020","unstructured":"Baumann A.; PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety. Haemophilia  2020,26(1),e11-e13","journal-title":"Haemophilia"},{"key":"ref=30","author":"Scott M.D.","year":"2019","unstructured":"Scott M.D.; Nakane N.;  Maurer-Spurej, E Cryoprotection of Platelets by Grafted Polymers Cryopreservation-Current Advances and Evaluations  2019","journal-title":"Maurer-Spurej, E Cryoprotection of Platelets by Grafted Polymers Cryopreservation-Current Advances and Evaluations"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1559-4106-8-14","volume":"8","author":"Sauter A.","year":"2013","unstructured":"Sauter A.; Richter G.; Micoulet A.; Martinez A.; Spatz J.P.; Appel S.; Effective polyethylene glycol passivation for the inhibition of surface interactions of peripheral blood mononuclear cells and platelets. Biointerphases  2013,8(1),14","journal-title":"Biointerphases"},{"key":"ref=32","author":"Maurer E.","year":"2011","unstructured":"Maurer E.; Scott M.D.; Kitamura N.; Cold storage of pegylated platelets at about or below 0\u00b0C.  2011"},{"key":"ref=33","author":"Tarrand J.","year":"2021","unstructured":"Tarrand J.; Andersson B.; Compositions and methods for prolonged cell storage.  2021"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1423-0410.2010.01419.x","volume":"100","author":"Greco C.A.","year":"2011","unstructured":"Greco C.A.; Maurer-Spurej E.; Scott M.D.; Kalab M.; Nakane N.; Ram\u00edrez-Arcos S.M.; PEGylation prevents bacteria-induced platelet activation and biofilm formation in platelet concentrates. Vox Sang  2011,100(3),336-339","journal-title":"Vox Sang"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.3892\/mmr.2017.7556","volume":"16","author":"Wufuer Y.","year":"2017","unstructured":"Wufuer Y.; Shan X.; Sailike M.; Adilaimu K.; Ma S.; Wang H.; GPVI-Fc-PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis. Mol Med Rep  2017,16(5),7561-7568","journal-title":"Mol Med Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/pharmaceutics11100514","volume":"11","author":"Bakhaidar R.","year":"2019","unstructured":"Bakhaidar R.; Green J.; Alfahad K.; Samanani S.; Moollan N.; O\u2019Neill S.; Ramtoola Z.; Effect of size and concentration of PLGA-PEG nanoparticles on activation and aggregation of washed human platelets. Pharmaceutics  2019,11(10),514","journal-title":"Pharmaceutics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.nano.2016.10.010","volume":"13","author":"Fuentes E.","year":"2017","unstructured":"Fuentes E.; Yameen B.; Bong S.J.; Salvador-Morales C.; Palomo I.; Vilos C.; Antiplatelet effect of differentially charged PEGylated lipid-polymer nanoparticles. Nanomedicine  2017,13(3),1089-1094","journal-title":"Nanomedicine"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2217\/nnm-2018-0063","volume":"13","author":"Mehrizi T.Z.","year":"2018","unstructured":"Mehrizi T.Z.; Ardestani M.S.; Molla Hoseini M.H.; Khamesipour A.; Mosaffa N.; Ramezani A.; Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major. Nanomedicine  2018,13(24),3129-3147","journal-title":"Nanomedicine"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10856-018-6122-9","volume":"29","author":"Mehrizi T.Z.","year":"2018","unstructured":"Mehrizi T.Z.; Ardestani M.S.; Khamesipour A.; Hoseini M.H.M.; Mosaffa N.; Anissian A.; Ramezani A.; Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major. J Mater Sci Mater Med  2018,29(8),125-138","journal-title":"J Mater Sci Mater Med"},{"key":"ref=40","first-page":"261","volume":"9","author":"Zadeh M.T.","year":"2022","unstructured":"Zadeh M.T.; Shafiee A.M.; Mirzaei M.J.; review study on the application of polymeric-based nanoparticles as a novel approach for enhancing the stability of albumins. Nanomed J  2022,9(4),261-272","journal-title":"Nanomed J"},{"key":"ref=41","volume":"2019","author":"Belousov A","year":"2019","unstructured":"Belousov A; Malygon E; Yavorskiy V; Belousova E; Stabilization of molecular structure membranes of preserved rbcs by means nanotechnology. Ann Med and Surg Case Rep: AMSCR  2019,2019(100001)","journal-title":"Ann Med and Surg Case Rep: AMSCR"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"9716","DOI":"10.3390\/ijms21249716","volume":"21","author":"Bakhaidar R.","year":"2020","unstructured":"Bakhaidar R.; O\u2019Neill S.; Ramtoola Z.; PLGA-PEG nanoparticles show minimal risks of interference with platelet function of human platelet-rich plasma. Int J Mol Sci  2020,21(24),9716","journal-title":"Int J Mol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"NA","DOI":"10.1002\/jbm.b.31558","volume":"9999B","author":"Wang W.","year":"2010","unstructured":"Wang W.; Xiong W.; Zhu Y.; Xu H.; Yang X.; Protective effect of PEGylation against poly(amidoamine) dendrimer-induced hemolysis of human red blood cells. J Biomed Mater Res B Appl Biomater  2010,9999B(1),NA","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5812\/ijb.17776","volume":"12","author":"Gholami Z.","year":"2014","unstructured":"Gholami Z.; Hashemi Najafabadi S.; Soleimani M.; Simultaneous camouflage of major and minor antigens on red blood cell surface with activated mPEGs. Iran J Biotechnol  2014,12(2),15-25","journal-title":"Iran J Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5772\/intechopen.68647","author":"Scott M.","year":"2017","unstructured":"Scott M.; Toyofuku W.; Yang X.; Raj M.; Kang N.; Immunocamouflaged RBC for alloimmunized patients. Transfusion Medicine and Scientific Developments Croatia  2017,23-42","journal-title":"Transfusion Medicine and Scientific Developments Croatia"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/milmed\/usz210","volume":"185","author":"Rzigalinski B.A.","year":"2020","unstructured":"Rzigalinski B.A.; Giovinco H.M.; Cheatham B.J.; Cerium oxide nanoparticles improve lifespan of stored blood. Mil Med  2020,185(S1),103-109","journal-title":"Mil Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/aor.12928","volume":"41","author":"Webster K.D.","year":"2017","unstructured":"Webster K.D.; Dahhan D.; Otto A.M.; Frosti C.L.; Dean W.L.; Chaires J.B.; Olsen K.W.; \u201cInside-Out\u201d PEGylation of bovine \u03b2-cross-linked hemoglobin. Artif Organs  2017,41(4),351-358","journal-title":"Artif Organs"},{"key":"ref=48","author":"Webster K.D.","year":"2016","unstructured":"Webster K.D.;  Development of\u201d inside-out\u201d PEGylated crosslinked hemoglobin polymers: Novel hemoglobin-based oxygen carriers (HBOC)  2016","journal-title":"Development of\u201d inside-out\u201d PEGylated crosslinked hemoglobin polymers: Novel hemoglobin-based oxygen carriers (HBOC)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.bbapap.2014.04.005","volume":"1844","author":"Wang Q.","year":"2014","unstructured":"Wang Q.; Sun L.; Ji S.; Zhao D.; Liu J.; Su Z.; Hu T.; Reversible protection of Cys-93(\u03b2) by PEG alters the structural and functional properties of the PEGylated hemoglobin. Biochim Biophys Acta Proteins Proteomics  2014,1844(7),1201-1207","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1016\/j.biomaterials.2012.07.015","volume":"33","author":"Chapanian R.","year":"2012","unstructured":"Chapanian R.; Constantinescu I.; Rossi N.A.A.; Medvedev N.; Brooks D.E.; Scott M.D.; Kizhakkedathu J.N.; Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells. Biomaterials  2012,33(31),7871-7883","journal-title":"Biomaterials"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1021\/bm4003943","volume":"14","author":"Chapanian R.","year":"2013","unstructured":"Chapanian R.; Constantinescu I.; Medvedev N.; Scott M.D.; Brooks D.E.; Kizhakkedathu J.N.; Therapeutic cells via functional modification: influence of molecular properties of polymer grafts on in vivo circulation, clearance, immunogenicity, and antigen protection. Biomacromolecules  2013,14(6),2052-2062","journal-title":"Biomacromolecules"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1016\/j.biomaterials.2011.12.041","volume":"33","author":"Wang D.","year":"2012","unstructured":"Wang D.; Toyofuku W.M.; Scott M.D.; The potential utility of methoxypoly(ethylene glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials  2012,33(10),3002-3012","journal-title":"Biomaterials"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.actbio.2015.11.022","volume":"31","author":"Leung V.L.","year":"2016","unstructured":"Leung V.L.; Kizhakkedathu J.N.; The mechanism and modulation of complement activation on polymer grafted cells. Acta Biomater  2016,31,252-263","journal-title":"Acta Biomater"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1089\/neu.2016.4656","volume":"34","author":"Brockman E.C.","year":"2017","unstructured":"Brockman E.C.; Jackson T.C.; Dixon C.E.; Bay\u026ar H.; Clark R.S.B.; Vagni V.; Feldman K.; Byrd C.; Ma L.; Hsia C.; Kochanek P.M.; Polynitroxylated pegylated hemoglobin\u2014a novel, small volume therapeutic for traumatic brain injury resuscitation: Comparison to whole blood and dose response evaluation. J Neurotrauma  2017,34(7),1337-1350","journal-title":"J Neurotrauma"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.29074\/ascls.24.4.227","volume":"24","author":"Moore M.S.","year":"2011","unstructured":"Moore M.S.; Okelberry E.; Cordingley K.; Drake A.; Robinett Z.; DePEGylation studies: PEG-RBC stability in conditions consistent with massive transfusion. Clin Lab Sci  2011,24(4),227-232","journal-title":"Clin Lab Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/ajh.24211","volume":"90","author":"Li L.","year":"2015","unstructured":"Li L.; Noumsi G.T.; Kwok Y.Y.E.; Moulds J.M.; Scott M.D.; Inhibition of phagocytic recognition of anti-D opsonized Rh D+ RBC by polymer-mediated immunocamouflage. Am J Hematol  2015,90(12),1165-1170","journal-title":"Am J Hematol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.biomaterials.2013.09.016","volume":"35","author":"Kyluik-Price D.L.","year":"2014","unstructured":"Kyluik-Price D.L.; Li L.; Scott M.D.; Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline. Biomaterials  2014,35(1),412-422","journal-title":"Biomaterials"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1016\/j.biomaterials.2011.12.053","volume":"33","author":"Chapanian R.","year":"2012","unstructured":"Chapanian R.; Constantinescu I.; Brooks D.E.; Scott M.D.; Kizhakkedathu J.N.; In vivo circulation, clearance, and biodistribution of polyglycerol grafted functional red blood cells. Biomaterials  2012,33(10),3047-3057","journal-title":"Biomaterials"},{"key":"ref=59","first-page":"13","volume":"18","author":"Haghdoost S.","year":"2015","unstructured":"Haghdoost S.; Hashemi-Najafabadi S.; Soleimani M.; Investigating the stability of polymer coating of methoxy polyethylene glycol activated by succinimidyl valerate on the surface of red blood cells under in vitro and in vivo conditions. Pathobiology Research  2015,18(2),13-26","journal-title":"Pathobiology Research"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1134\/S1990519X17020109","volume":"11","author":"Zemlianskykh N.G.","year":"2017","unstructured":"Zemlianskykh N.G.; Babijchuk L.A.; The changes in erythrocyte Ca2+-ATPase activity induced by PEG-1500 and low temperatures. Cell Tissue Biol  2017,11(2),104-110","journal-title":"Cell Tissue Biol"},{"key":"ref=61","first-page":"461","author":"Abuchowski A.","year":"2016","unstructured":"Abuchowski A.;  PEGylated bovine carboxyhemoglobin (SANGUINATE\u2122): results of clinical safety testing and use in patients Oxygen transport to tissue XXXVII  2016,461-467","journal-title":"PEGylated bovine carboxyhemoglobin (SANGUINATE\u2122): results of clinical safety testing and use in patients Oxygen transport to tissue XXXVII"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0267659119850681","volume":"35","author":"Romito B.T.","year":"2020","unstructured":"Romito B.T.; McBroom M.M.; Bryant D.; Gamez J.; Merchant A.; Hill S.E.; The effect of SANGUINATE \u00ae (PEGylated carboxyhemoglobin bovine) on cardiopulmonary bypass functionality using a bovine whole blood model of normovolemic hemodilution. Perfusion  2020,35(1),19-25","journal-title":"Perfusion"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/aor.12934","volume":"41","author":"Abuchowski A.","year":"2017","unstructured":"Abuchowski A.; SANGUINATE (PEGylated carboxyhemoglobin bovine): Mechanism of action and clinical update. Artif Organs  2017,41(4),346-350","journal-title":"Artif Organs"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bjhh.2016.08.004","volume":"39","author":"Misra H.","year":"2017","unstructured":"Misra H.; Bainbridge J.; Berryman J.; Abuchowski A.; Galvez K.M.; Uribe L.F.; Hernandez A.L.; Sosa N.R.; A Phase Ib open label, randomized, safety study of SANGUINATE\u2122 in patients with sickle cell anemia. Rev Bras Hematol Hemoter  2017,39(1),20-27","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/21691401.2012.762370","volume":"41","author":"Ananthakrishnan R.","year":"2013","unstructured":"Ananthakrishnan R.; Li Q.; O\u2019Shea K.M.; Quadri N.; Wang L.; Abuchowski A.; Schmidt A.M.; Ramasamy R.; Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia\/reperfusion injury in diabetic and normal mice. Artif Cells Nanomed Biotechnol  2013,41(6),428-436","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.969.969","author":"Buontempo P.","year":"2017","unstructured":"Buontempo P.; Jubin R.G.; Buontempo C.; Real R.; Kazo F.; O\u2019Brien S.;  Pegylated carboxyhemoglobin bovine (SANGUINATE\u00ae) restores RBCs roundness and reduces pain during a sickle cell vaso-occlusive crisis  2017","journal-title":"Pegylated carboxyhemoglobin bovine (SANGUINATE\u00ae) restores RBCs roundness and reduces pain during a sickle cell vaso-occlusive crisis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/SHK.0000000000001082","volume":"52","author":"Nugent W.H.","year":"2019","unstructured":"Nugent W.H.; Cestero R.F.; Ward K.; Jubin R.; Abuchowski A.; Song B.K.; Effects of Sanguinate on systemic and microcirculatory variables in a model of prolonged hemorrhagic shock. Shock  2019,52(1S),108-115","journal-title":"Shock"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/21691401.2014.885444","volume":"43","author":"Wang Q.","year":"2015","unstructured":"Wang Q.; Hu T.; Sun L.; Ji S.; Zhao D.; Liu J.; Ma G.; Su Z.; CO binding improves the structural, functional, physical and antioxidation properties of the PEGylated hemoglobin. Artif Cells Nanomed Biotechnol  2015,43(1),18-25","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1039\/C9BM01773A","volume":"8","author":"Cooper C.E.","year":"2020","unstructured":"Cooper C.E.; Silkstone G.G.A.; Simons M.; Gretton S.; Rajagopal B.S.; Allen-Baume V.; Syrett N.; Shaik T.; Popa G.; Sheng X.; Bird M.; Choi J.W.; Piano R.; Ronda L.; Bettati S.; Paredi G.; Mozzarelli A.; Reeder B.J.; Engineering hemoglobin to enable homogenous PEGylation without modifying protein functionality. Biomater Sci  2020,8(14),3896-3906","journal-title":"Biomater Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1021\/acs.biomac.8b00728","volume":"19","author":"Matsuhira T.","year":"2018","unstructured":"Matsuhira T.; Kure T.; Yamamoto K.; Sakai H.; Analysis of dimeric \u03b1\u03b2 subunit exchange between pegylated and native hemoglobins (\u03b1 2 \u03b2 2 Tetramer) in an equilibrated state by intramolecular \u03b2-cross-linking. Biomacromolecules  2018,19(8),3412-3420","journal-title":"Biomacromolecules"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/21691401.2014.885443","volume":"43","author":"Meng F.","year":"2015","unstructured":"Meng F.; Tsai A.G.; Intaglietta M.; Acharya S.A.; PEGylation of \u03b1-Hb using succinimidyl propionic acid PEG 5K: Conjugation chemistry and PEG shell structure dictate respectively the oxygen affinity and resuscitation fluid like properties of PEG \u03b1-Hbs. Artif Cells Nanomed Biotechnol  2015,43(4),270-281","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/10731199.2010.501756","volume":"39","author":"Hu T.","year":"2011","unstructured":"Hu T.; Li D.; Meng F.; Prabhakaran M.; Acharya S.A.; Increased inter dimeric interaction of oxy hemoglobin is necessary for attenuation of reductive pegylation promoted dissociation of tetramer. Artif Cells Blood Substit Immobil Biotechnol  2011,39(2),69-78","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1471-2091-12-66","volume":"12","author":"Coppola D.","year":"2011","unstructured":"Coppola D.; Bruno S.; Ronda L.; Viappiani C.; Abbruzzetti S.; di Prisco G.; Verde C.; Mozzarelli A.; Low affinity PEGylated hemoglobin from trematomus bernacchii, a model for hemoglobin-based blood substitutes. BMC Biochem  2011,12(1),66","journal-title":"BMC Biochem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/aor.13384","volume":"42","author":"Kawaguchi A.T.","year":"2018","unstructured":"Kawaguchi A.T.; Salybekov A.A.; Yamano M.; Kitagishi H.; Sekine K.; Tamaki T.; PEGylated carboxyhemoglobin bovine (SANGUINATE) ameliorates myocardial infarction in a rat model. Artif Organs  2018,42(12),1174-1184","journal-title":"Artif Organs"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/btpr.2380","volume":"33","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Wang L.; Yu W.; Gao D.; You G.; Li P.; Zhang S.; Zhang J.; Hu T.; Zhao L.; Zhou H.; A PEGylated bovine hemoglobin as a potent hemoglobin-based oxygen carrier. Biotechnol Prog  2017,33(1),252-260","journal-title":"Biotechnol Prog"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4928.4928","author":"Nalley C.M.","year":"2014","unstructured":"Nalley C.M.; Abuchowski A.; Hsu S.; Lanzkron S.;  Successful Use of Pegylated Carboxyhemoglobin Bovine As an Emergency Treatment for Severe Anemia in a Patient with Sickle Cell Disease and Hyperhemolysis: A Case Report  2014","journal-title":"Successful Use of Pegylated Carboxyhemoglobin Bovine As an Emergency Treatment for Severe Anemia in a Patient with Sickle Cell Disease and Hyperhemolysis: A Case Report"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2991\/emeit.2012.222","author":"Zhang L.","year":"2012","unstructured":"Zhang L.; Wang X.; Qi D.; The study of terminated PEG maleimide synthesis and modification of hemoglobin. Proceedings of the 2nd International Conference on Electronic and Mechanical Engineering and Information Technology (EMEIT 2012)  2012,1951-6851","journal-title":"Proceedings of the 2nd International Conference on Electronic and Mechanical Engineering and Information Technology (EMEIT 2012)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e006505","DOI":"10.1161\/JAHA.117.006505","volume":"6","author":"Cao S.","year":"2017","unstructured":"Cao S.; Zhang J.; Ma L.; Hsia C.J.C.; Koehler R.C.; Transfusion of polynitroxylated pegylated hemoglobin stabilizes pial arterial dilation and decreases infarct volume after transient middle cerebral artery occlusion. J Am Heart Assoc  2017,6(9),e006505","journal-title":"J Am Heart Assoc"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/CCM.0b013e318206b1fa","volume":"39","author":"Shellington D.K.","year":"2011","unstructured":"Shellington D.K.; Du L.; Wu X.; Exo J.; Vagni V.; Ma L.; Janesko-Feldman K.; Clark R.S.B.; Bayir H.; Dixon C.E.; Jenkins L.W.; Hsia C.J.C.; Kochanek P.M.; Polynitroxylated pegylated hemoglobin: A novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice. Crit Care Med  2011,39(3),494-505","journal-title":"Crit Care Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/jcbfm.2013.104","volume":"33","author":"Brockman E.C.","year":"2013","unstructured":"Brockman E.C.; Bayir H.; Blasiole B.; Shein S.L.; Fink E.L.; Dixon C.E.; Clark R.S.B.; Vagni V.A.; Ma L.; Hsia C.J.C.; Tisherman S.A.; Kochanek P.M.; Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice. J Cereb Blood Flow Metab  2013,33(9),1457-1464","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"728","DOI":"10.34172\/apb.2021.082","volume":"11","author":"Akbarzadehlaleh P.","year":"2020","unstructured":"Akbarzadehlaleh P.; Mirzaei M.; Mashahdi-keshtiban M.; Heidari H.R.; The effect of length and structure of attached polyethylene glycol chain on hydrodynamic radius, and separation of pegylated human serum albumin by chromatography. Adv Pharm Bull  2020,11(4),728-738","journal-title":"Adv Pharm Bull"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejpb.2011.05.003","volume":"79","author":"Plesner B.","year":"2011","unstructured":"Plesner B.; Fee C.J.; Westh P.; Nielsen A.D.; Effects of PEG size on structure, function and stability of PEGylated BSA. Eur J Pharm Biopharm  2011,79(2),399-405","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5582\/bst.2012.v6.2.81","volume":"6","author":"Zhao T.","year":"2012","unstructured":"Zhao T.; Yang Y.; Zong A.; Tan H.; Song X.; Meng S.; Song C.; Pang G.; Wang F.; N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention. Biosci Trends  2012,6(2),81-88","journal-title":"Biosci Trends"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.15171\/apb.2016.043","volume":"6","author":"Akbarzadehlaleh P.","year":"2016","unstructured":"Akbarzadehlaleh P.; Mirzaei M.; Mashahdi-Keshtiban M.; Shamsasenjan K.; Heydari H.; PEGylated human serum albumin: Review of PEGylation, purification and characterization methods. Adv Pharm Bull  2016,6(3),309-317","journal-title":"Adv Pharm Bull"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.saa.2011.08.065","volume":"83","author":"Yu M.","year":"2011","unstructured":"Yu M.; Ding Z.; Jiang F.; Ding X.; Sun J.; Chen S.; Lv G.; Analysis of binding interaction between pegylated puerarin and bovine serum albumin by spectroscopic methods and dynamic light scattering. Spectrochim Acta A Mol Biomol Spectrosc  2011,83(1),453-460","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1537-2995.2012.03679.x","volume":"53","author":"Hightower C.M.","year":"2013","unstructured":"Hightower C.M.; Salazar V\u00e1zquez B.Y.; Cabrales P.; Tsai A.G.; Acharya S.A.; Intaglietta M.; Plasma expander and blood storage effects on capillary perfusion in transfusion after hemorrhage. Transfusion  2013,53(1),49-59","journal-title":"Transfusion"},{"key":"ref=87","year":"2017","unstructured":"Characterization of Multi-Albumin Pegylated Complexes Synthesized Using\" Click\" Chemistry as Drug Delivery Systems Hill, JA 2017","journal-title":"Characterization of Multi-Albumin Pegylated Complexes Synthesized Using\" Click\" Chemistry as Drug Delivery Systems"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biochi.2014.05.009","volume":"104","author":"Samanta N.","year":"2014","unstructured":"Samanta N.; Mahanta D.D.; Hazra S.; Kumar G.S.; Mitra R.K.; Short chain polyethylene glycols unusually assist thermal unfolding of human serum albumin. Biochimie  2014,104,81-89","journal-title":"Biochimie"},{"key":"ref=89","first-page":"47","volume":"5","author":"Hoorang M.","year":"2019","unstructured":"Hoorang M.; Tamaddon A.; Yousefi G.; Synthesis of PEGylated human serum albumin by maleimide-thiol chemistry and histopathological evaluation in a mice model of carrageenan-induced inflammation. Trends Pharmacol Sci  2019,5(1),47-56","journal-title":"Trends Pharmacol Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1248\/bpb.35.280","volume":"35","author":"Zhao T.","year":"2012","unstructured":"Zhao T.; Cheng Y.N.; Tan H.N.; Liu J.F.; Xu H.L.; Pang G.L.; Wang F.S.; Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice. Biol Pharm Bull  2012,35(3),280-288","journal-title":"Biol Pharm Bull"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"H2489","DOI":"10.1152\/ajpheart.01090.2011","volume":"302","author":"Sriram K.","year":"2012","unstructured":"Sriram K.; Tsai A.G.; Cabrales P.; Meng F.; Acharya S.A.; Tartakovsky D.M.; Intaglietta M.; PEG-albumin supraplasma expansion is due to increased vessel wall shear stress induced by blood viscosity shear thinning. Am J Physiol Heart Circ Physiol  2012,302(12),H2489-H2497","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=92","first-page":"704","volume":"77","author":"Chatpun S.","year":"2011","unstructured":"Chatpun S.; Cabrales P.; Effects on cardiac function of a novel low viscosity plasma expander based on polyethylene glycol conjugated albumin. Minerva Anestesiol  2011,77(7),704-714","journal-title":"Minerva Anestesiol"},{"key":"ref=93","author":"Acharya S.A.","year":"2014","unstructured":"Acharya S.A.; Intaglietta M.; Method of enhancing efficacy of blood transfusions.  2014"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ajem.2012.05.031","volume":"31","author":"Chatpun S.","year":"2013","unstructured":"Chatpun S.; Nacharaju P.; Cabrales P.; Improving cardiac function with new-generation plasma volume expanders. Am J Emerg Med  2013,31(1),54-63","journal-title":"Am J Emerg Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/10731199.2011.579568","volume":"40","author":"Ananda K.","year":"2012","unstructured":"Ananda K.; Manjula B.N.; Meng F.; Acharya V.N.; Intaglietta M.; Acharya S.A.; Packing density of the PEG-shell in PEG-albumins: PEGylation induced viscosity and COP are inverse correlate of packing density. Artif Cells Blood Substit Immobil Biotechnol  2012,40(1-2),14-27","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"075101","DOI":"10.1063\/5.0038306","volume":"154","author":"Munasinghe A.","year":"2021","unstructured":"Munasinghe A.; Mathavan A.; Mathavan A.; Lin P.; Colina C.M.; Atomistic insight towards the impact of polymer architecture and grafting density on structure-dynamics of PEGylated bovine serum albumin and their applications. J Chem Phys  2021,154(7),075101","journal-title":"J Chem Phys"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1021\/acs.jpcb.8b12268","volume":"123","author":"Munasinghe A.","year":"2019","unstructured":"Munasinghe A.; Mathavan A.; Mathavan A.; Lin P.; Colina C.M.; Molecular insight into the protein\u2013polymer interactions in N-terminal PEGylated bovine serum albumin. J Phys Chem B  2019,123(25),5196-5205","journal-title":"J Phys Chem B"},{"key":"ref=98","author":"Di Minno M.N.D.","year":"2020","unstructured":"Di Minno M.N.D.; Di Minno A.; Calcaterra I.; Cimino E.; Dell\u2019Aquila F.; Franchini M. Eds.;  Enhanced half-life recombinant factor VIII concentrates for hemophilia A: insights from pivotal and extension studies Seminars in Thrombosis and Hemostasis  2020","journal-title":"Enhanced half-life recombinant factor VIII concentrates for hemophilia A: insights from pivotal and extension studies Seminars in Thrombosis and Hemostasis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/hae.12198","volume":"19","author":"Pastoft A.E.","year":"2013","unstructured":"Pastoft A.E.; Ezban M.; Tranholm M.; Lykkesfeldt J.; Lauritzen B.; Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. Haemophilia  2013,19(6),913-919","journal-title":"Haemophilia"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","volume":"121","author":"Stennicke H.R.","year":"2013","unstructured":"Stennicke H.R.; Kjalke M.; Karpf D.M.; Balling K.W.; Johansen P.B.; Elm T.; \u00d8vlisen K.; M\u00f6ller F.; Holmberg H.L.; Gudme C.N.; Persson E.; Hilden I.; Pelzer H.; Rahbek-Nielsen H.; Jespersgaard C.; Bogsnes A.; Pedersen A.A.; Kristensen A.K.; Peschke B.; Kappers W.; Rode F.; Thim L.; Tranholm M.; Ezban M.; Olsen E.H.N.; Bj\u00f8rn S.E.; A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood  2013,121(11),2108-2116","journal-title":"Blood"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jth.12161","volume":"11","author":"Tiede A.","year":"2013","unstructured":"Tiede A.; Brand B.; Fischer R.; Kavakli K.; Lentz S.R.; Matsushita T.; Rea C.; Knobe K.; Viuff D.; Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost  2013,11(4),670-678","journal-title":"J Thromb Haemost"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"8496246","DOI":"10.1155\/2017\/8496246","volume":"2017","author":"Rasmussen C.E.","year":"2017","unstructured":"Rasmussen C.E.; Nowak J.; Larsen J.M.; Moore E.; Bell D.; Liu K.C.; Long-term safety of PEGylated coagulation factor VIII in the immune-deficient Rowett nude rat. J Toxicol  2017,2017,8496246","journal-title":"J Toxicol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/hae.13246","volume":"23","author":"Hampton K.","year":"2017","unstructured":"Hampton K.; Chowdary P.; Dunkley S.; Ehrenforth S.; Jacobsen L.; Neff A.; Santagostino E.; Sathar J.; Takedani H.; Takemoto C.M.; N\u00e9grier C.; First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Haemophilia  2017,23(5),689-696","journal-title":"Haemophilia"},{"key":"ref=104","author":"Chowdary P.","year":"2020","unstructured":"Chowdary P.;  N8\u2010GP: A new extended half\u2010life recombinant factor VIII product for hemophilia A  2020","journal-title":"N8\u2010GP: A new extended half\u2010life recombinant factor VIII product for hemophilia A"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1160\/TH16-06-0444","volume":"117","author":"Giangrande P.","year":"2017","unstructured":"Giangrande P.; Andreeva T.; Chowdary P.; Ehrenforth S.; Hanabusa H.; Leebeek F.W.G.; Lentz S.R.; Nemes L.; Poulsen L.H.; Santagostino E.; You C.W.; Ong Clausen W.H.; J\u00f6nsson P.G.; Oldenburg J.; Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost  2017,117(2),252-261","journal-title":"Thromb Haemost"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1160\/TH17-03-0166","volume":"117","author":"Meunier S.","year":"2017","unstructured":"Meunier S.; Alamelu J.; Ehrenforth S.; Hanabusa H.; Karim F.A.; Kavakli K.; Khodaie M.; Staber J.; Stasyshyn O.; Yee D.; Rageliene L.; Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost  2017,117(9),1705-1713","journal-title":"Thromb Haemost"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/jth.14013","volume":"16","author":"Rode F.","year":"2018","unstructured":"Rode F.; Almholt K.; Petersen M.; Kreilgaard M.; Kjalke M.; Karpf D.M.; Groth A.V.; Johansen P.B.; Larsen L.F.; Loftager M.; Haaning J.; Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8\u2010GP) and development of a human pharmacokinetic prediction model. J Thromb Haemost  2018,16(6),1141-1152","journal-title":"J Thromb Haemost"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0192623319852300","volume":"47","author":"Ivens I.A.","year":"2019","unstructured":"Ivens I.A.; Banczyk D.; Gutberlet K.; Jackman S.; Vaul\u00e9on S.; Frisk A.L.; Nonclinical safety assessment of a long-acting recombinant PEGylated factor eight (BAY 94-9027) with a 60 kDa PEG. Toxicol Pathol  2019,47(5),585-597","journal-title":"Toxicol Pathol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","volume":"99","author":"Solms A.","year":"2020","unstructured":"Solms A.; Shah A.; Berntorp E.; Tiede A.; Iorio A.; Linardi C.; Ahsman M.; Mancuso M.E.; Zhivkov T.; Lissitchkov T.; Direct comparison of two extended half-life PEGylated recombinant FVIII products: A randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol  2020,99(11),2689-2698","journal-title":"Ann Hematol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1111\/hae.13963","volume":"26","author":"Santagostino E.","year":"2020","unstructured":"Santagostino E.; Kenet G.; Fischer K.; Biss T.; Ahuja S.; Steele M.; Mart\u00ednez M.; Male C.; van Geet C.; Mondelaers V.; Kaleva V.; Stoyanova-Deleva A.; Bobev D.; Blanchette V.; Zanon E.; Gagliano F.; Rageliene L.; Peters M.; Mlynarski W.; Badowska W.; Serban M.; Rusen L.; Uscatescu V.; Will A.; Payne J.; Tunstall O.; Kerlin B.; Gruppo R.; Eyster M.E.; Ducore J.; Schwartz J.; PROTECT VIII kids: BAY 94\u20109027 (PEGylated recombinant factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia  2020,26(3),e55-e65","journal-title":"Haemophilia"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/hae.13119","volume":"23","author":"Mullins E.S.","year":"2017","unstructured":"Mullins E.S.; Stasyshyn O.; Alvarez-Rom\u00e1n M.T.; Osman D.; Liesner R.; Engl W.; Sharkhawy M.; Abbuehl B.E.; Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia  2017,23(2),238-246","journal-title":"Haemophilia"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","volume":"126","author":"Konkle B.A.","year":"2015","unstructured":"Konkle B.A.; Stasyshyn O.; Chowdary P.; Bevan D.H.; Mant T.; Shima M.; Engl W.; Dyck-Jones J.; Fuerlinger M.; Patrone L.; Ewenstein B.; Abbuehl B.; Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood  2015,126(9),1078-1085","journal-title":"Blood"},{"key":"ref=113","author":"Schermeyer M-T.","year":"2017","unstructured":"Schermeyer M-T.; W\u00f6ll A.K.; Kokke B.; Eppink M.; Hubbuch J. Eds.;  Characterization of highly concentrated antibody solution-A toolbox for the description of protein long-term solution stability MAbs  2017","journal-title":"Characterization of highly concentrated antibody solution-A toolbox for the description of protein long-term solution stability MAbs"},{"key":"ref=114","first-page":"275","author":"Heywood S.P.","year":"2009","unstructured":"Heywood S.P.; Humphreys D.P.;  Polymer Fusions to Increase Antibody Half-Lives: PEGylation and Other Modifications  2009,275","journal-title":"Polymer Fusions to Increase Antibody Half-Lives: PEGylation and Other Modifications"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","volume":"28","author":"Pasut G.","year":"2014","unstructured":"Pasut G.; Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs  2014,28(S1),15-23","journal-title":"BioDrugs"},{"key":"ref=116","first-page":"233","author":"Jev\u0161evar S.","year":"2012","unstructured":"Jev\u0161evar S.; Kusterle M.; Kenig M.;  PEGylation of antibody fragments for half-life extension Antibody methods and protocols  2012,233-246","journal-title":"PEGylation of antibody fragments for half-life extension Antibody methods and protocols"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.xphs.2016.05.021","volume":"105","author":"Toprani V.M.","year":"2016","unstructured":"Toprani V.M.; Joshi S.B.; Kueltzo L.A.; Schwartz R.M.; Middaugh C.R.; Volkin D.B.; A micro\u2013polyethylene glycol precipitation assay as a relative solubility screening tool for monoclonal antibody design and formulation development. J Pharm Sci  2016,105(8),2319-2327","journal-title":"J Pharm Sci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1039\/D0TB02911D","volume":"9","author":"Lee W.","year":"2021","unstructured":"Lee W.; Bobba K.N.; Kim J.Y.; Park H.; Bhise A.; Kim W.; Lee K.; Rajkumar S.; Nam B.; Lee K.C.; Lee S.H.; Ko S.; Lee H.J.; Jung S.T.; Yoo J.; A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images. J Mater Chem B Mater Biol Med  2021,9(13),2993-2997","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejpb.2020.03.011","volume":"151","author":"W\u00e4lchli R.","year":"2020","unstructured":"W\u00e4lchli R.; Fanizzi F.; Massant J.; Arosio P.; Relationship of PEG-induced precipitation with protein-protein interactions and aggregation rates of high concentration mAb formulations at 5\u00b0C. Eur J Pharm Biopharm  2020,151,53-60","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/elsc.201900110","volume":"20","author":"Satzer P.","year":"2020","unstructured":"Satzer P.; Burgstaller D.; Krepper W.; Jungbauer A.; Fractal dimension of antibody\u2010PEG precipitate: Light microscopy for the reconstruction of 3D precipitate structures. Eng Life Sci  2020,20(3-4),67-78","journal-title":"Eng Life Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1021\/acs.molpharmaceut.5b00749","volume":"13","author":"Chan L.J.","year":"2016","unstructured":"Chan L.J.; Ascher D.B.; Yadav R.; Bulitta J.B.; Williams C.C.; Porter C.J.H.; Landersdorfer C.B.; Kaminskas L.M.; Conjugation of 10 kDa linear PEG onto trastuzumab Fab\u2032 is sufficient to significantly enhance lymphatic exposure while preserving in vitro biological activity. Mol Pharm  2016,13(4),1229-1241","journal-title":"Mol Pharm"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/molecules24213835","volume":"24","author":"Kholodenko I.V.","year":"2019","unstructured":"Kholodenko I.V.; Kalinovsky D.V.; Svirshchevskaya E.V.; Doronin I.I.; Konovalova M.V.; Kibardin A.V.; Shamanskaya T.V.; Larin S.S.; Deyev S.M.; Kholodenko R.V.; Multimerization through pegylation improves pharmacokinetic properties of scFv fragments of GD2-specific antibodies. Molecules  2019,24(21),3835","journal-title":"Molecules"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","volume":"187","author":"Koussoroplis S.J.","year":"2014","unstructured":"Koussoroplis S.J.; Paulissen G.; Tyteca D.; Goldansaz H.; Todoroff J.; Barilly C.; Uyttenhove C.; Van Snick J.; Cataldo D.; Vanbever R.; PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release  2014,187,91-100","journal-title":"J Control Release"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1007\/s11095-016-2017-y","volume":"33","author":"Reichard E.E.","year":"2016","unstructured":"Reichard E.E.; Nanaware-Kharade N.; Gonzalez G.A.; Thakkar S.; Owens S.M.; Peterson E.C.; PEGylation of a high-affinity anti-(+) methamphetamine single chain antibody fragment extends functional half-life by reducing clearance. Pharm Res  2016,33(12),2954-2966","journal-title":"Pharm Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2017.12.009","volume":"272","author":"Patil H.P.","year":"2018","unstructured":"Patil H.P.; Freches D.; Karmani L.; Duncan G.A.; Ucakar B.; Suk J.S.; Hanes J.; Gallez B.; Vanbever R.; Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation. J Control Release  2018,272,62-71","journal-title":"J Control Release"},{"key":"ref=126","year":"2016","unstructured":"Storage stability studies of anti-VEGF FpF antibody mimetics. Khalili, H.; Brocchini, S.; Khaw, P.T.; Filippov, S., Eds.; 2016 AAPS Annual Meeting and Exposition  2016","journal-title":"2016 AAPS Annual Meeting and Exposition"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40199-018-0215-3","volume":"26","author":"Davarpanah F.","year":"2018","unstructured":"Davarpanah F.; Khalili Yazdi A.; Barani M.; Mirzaei M.; Torkzadeh-Mahani M.; Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes. Daru  2018,26(1),57-64","journal-title":"Daru"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/adhm.201600263","volume":"5","author":"Howard C.B.","year":"2016","unstructured":"Howard C.B.; Fletcher N.; Houston Z.H.; Fuchs A.V.; Boase N.R.B.; Simpson J.D.; Raftery L.J.; Ruder T.; Jones M.L.; de Bakker C.J.; Mahler S.M.; Thurecht K.J.; Overcoming instability of antibody\u2010nanomaterial conjugates: Next generation targeted nanomedicines using bispecific antibodies. Adv Healthc Mater  2016,5(16),2055-2068","journal-title":"Adv Healthc Mater"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/ijms17040491","volume":"17","author":"Selis F.","year":"2016","unstructured":"Selis F.; Foc\u00e0 G.; Sandomenico A.; Marra C.; Di Mauro C.; Saccani Jotti G.; Scaramuzza S.; Politano A.; Sanna R.; Ruvo M.; Tonon G.; Pegylated trastuzumab fragments acquire an increased in vivo stability but show a largely reduced affinity for the target antigen. Int J Mol Sci  2016,17(4),491","journal-title":"Int J Mol Sci"},{"key":"ref=130","first-page":"1670","volume":"17","author":"Kim S-H.","year":"2007","unstructured":"Kim S-H.; Lee Y-S.; Hwang S-Y.; Bae G-W.; Nho K.; Kang SW.; Kwak Y.G.; Moon C.S.; Han Y.S.; Kim T.Y.; Kho W.G.; Effects of PEGylated scFv antibodies against Plasmodium vivax duffy binding protein on the biological activity and stability in vitro. J Microbiol Biotechnol  2007,17(10),1670-1674","journal-title":"J Microbiol Biotechnol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijpharm.2017.02.021","volume":"521","author":"Freches D.","year":"2017","unstructured":"Freches D.; Patil H.P.; Machado Franco M.; Uyttenhove C.; Heywood S.; Vanbever R.; PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab\u2019 antibody fragment after pulmonary delivery in three different species. Int J Pharm  2017,521(1-2),120-129","journal-title":"Int J Pharm"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230522091958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217130\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230522091958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T12:12:20Z","timestamp":1709899940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217130\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666230522091958","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}